Waldenstrom Macroglobulinemia

The impact of dose-intensity reduction in Waldenstrom macroglobulinemia has not been explored.

The median progression-free survival was not reached after a median follow-up of 22 months.

Ibrutinib — a Bruton tyrosine kinase inhibitor — is currently used among patients with WM who have previously received treatment. This prospective, phase 2 study sought to determine its efficacy as a first-line therapy in treatment-naive patients.

Ibrutinib is used among patients with WM who have previously received treatment, but its efficacy as a first-line therapy among treatment-naive patients is unknown.

In patients with R/R WM, the overall response rate was 87%, with 4% of patients achieving a very good partial response.